Controversial Vaccine Trial in Africa Moves Forward Despite Ethical Concerns

A controversial medical research trial that will withhold hepatitis B vaccines from some newborns in Guinea-Bissau has been given the green light to move forward. The study, which was previously suspended following international criticism, has now received approval from an ethics committee at the University of Southern Denmark. This decision has sparked renewed debate among health professionals about the safety and ethics of testing on infants in developing countries.

The trial aims to enroll 14,000 infants. Under the research plan, half of the babies will receive the standard hepatitis B vaccine at birth, while the other half will not receive it for the first six weeks of life. Hepatitis B is a serious virus that can lead to liver damage, cancer, and early death. By delaying the vaccine, critics argue that the study intentionally leaves these infants vulnerable to a disease that is easily prevented.

According to The Guardian, the project is a key part of the vaccine vision for Robert F. Kennedy Jr., the secretary of the U.S. Department of Health and Human Services. Kennedy has previously expressed skepticism about the safety and effectiveness of many common vaccines. At a recent conference, he praised the Danish researchers leading the study and suggested that this kind of research fits the current administration’s goals, which include reducing the number of vaccine recommendations in the United States.

However, the project faces significant opposition. Stig Børsen Hansen, a reviewer who helped present the study to the Danish committee, resigned from his position in protest last week. He described the trial as a "lottery" where newborns are forced to participate in a test that could cause them permanent harm. "They contract hepatitis B in the context of being part of a research project," Hansen said, noting that the infection would happen by design rather than by accident. Three other members of the ethics committee also resigned in protest against the decision to proceed.

Experts in the United States have also raised alarms. Paul Offit, an infectious disease physician at Children’s Hospital of Philadelphia, stated that this type of trial would never be allowed in the U.S. due to strict ethical rules. Offit argued that the researchers are taking advantage of a developing nation, questioning whether the organizers believe that children in Africa are more expendable than those in the West. He noted that Kennedy’s ultimate goal appears to be ending the use of the birth dose of the hepatitis B vaccine in the United States.

Financial support for the project remains a point of contention. Ars Technica reports that the U.S. Centers for Disease Control and Prevention (CDC) has set aside $1.6 million for the trial. This funding would be taken from global health programs that might otherwise be used to fight other urgent health crises, such as the Ebola outbreak currently affecting the Democratic Republic of the Congo. The project will also receive private funding from the Pershing Square Foundation and the Bluebell Foundation.

In January, the minister of public health for Guinea-Bissau, Quinhin Nantote, had announced that the study was suspended because there was not enough coordination or agreement on its design. While the project has now been approved, details of the updated plan have not been made public. According to reports, the new protocol involves testing mothers for the virus before birth. If a mother tests positive, her baby will receive the vaccine and will not be part of the trial. However, babies of mothers who test negative may still be enrolled in the study.

The researchers leading the project, Christine Stabell Benn and Peter Aaby, are currently under investigation by Danish authorities. They face allegations of scientific misconduct and falsification related to their previous work. Despite these investigations and the ongoing outcry from the global medical community, the trial is expected to continue. Neither the CDC, the Danish research team, nor the foundations providing the money have responded to requests for comment regarding the ethical concerns raised by the study.